Medicare Enrolled
Dr. John Paul Kelada, MD
Emergency Medicine · Roseville, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kelada from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kelada?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kelada
Dr. John Paul Kelada is an emergency medicine specialist in Roseville, CA, with 10 years of NPI registration. Based on federal Medicare data, Dr. Kelada performed 1,697 Medicare services across 1,236 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kelada received a total of $13,010 from 60 pharmaceutical and/or device companies across 690 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in emergency medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kelada is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years in practice
▲ Top 2% volume in CA
$13,010 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,697
Medicare services
Top 2% in CA for emergency medicine
1,236
Unique beneficiaries
$90
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~170 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
674 | $97 | $275 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
158 | $138 | $360 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
142 | $76 | $225 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
90 | $76 | $200 |
| Annual alcohol misuse screening, 5 to 15 minutes | 72 | $20 | $35 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
70 | $124 | $300 |
| Home health agency supervision, complex multidisciplinary care Supervision by a physician or allowed practitioner for a patient receiving Medicare-covered services from a participating home health agency. This involves complex and multidisciplinary care modalities, with the patient not present during the supervision. |
59 | $81 | $200 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
56 | $33 | $75 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
51 | $72 | $89 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
51 | $11 | $60 |
| Annual depression screening | 46 | $20 | $34 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
40 | $128 | $300 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
36 | $238 | $400 |
| Online digital evaluation for established patient, 5-10 minutes This service involves an online digital evaluation and management visit for an established patient. It covers a total time of 5 to 10 minutes over a period of up to 7 days. |
35 | $11 | $50 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
33 | $45 | $80 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
19 | $33 | $75 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
18 | $282 | $342 |
| COVID-19 vaccine administration Administration of a single dose of the coronavirus vaccine. |
12 | $44 | $65 |
| COVID-19 vaccine (Pfizer bivalent) Administration of a 30 mcg dose of the SARS-CoV-2 vaccine via intramuscular injection. |
12 | $128 | $200 |
| Annual intensive behavioral therapy for cardiovascular disease, 15 minutes A yearly, in-person session focused on intensive behavioral therapy to help manage cardiovascular disease. The session lasts for 15 minutes and is conducted with the patient individually. |
12 | $27 | $41 |
| Transitional care management services, moderate complexity Services provided to coordinate care during the transition from an inpatient or other facility setting back to the community. This includes follow-up and management of a health problem of at least moderate complexity. |
11 | $175 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$13,010
Total received (2018-2024)
Avg $1,859/year across 7 years
Top 2% in CA for emergency medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
690
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,601 (96.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$409 (3.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,555
2023
$2,496
2022
$2,960
2021
$2,605
2020
$1,583
2019
$785
2018
$26
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$274
Novo Nordisk Inc
$237
GlaxoSmithKline, LLC.
$221
Lilly USA, LLC
$212
Boehringer Ingelheim Pharmaceuticals, Inc.
$190
AstraZeneca Pharmaceuticals LP
$182
PFIZER INC.
$174
ViiV Healthcare Company
$151
Astellas Pharma US Inc
$136
Bayer Healthcare Pharmaceuticals Inc.
$136
Merck Sharp & Dohme LLC
$86
Exact Sciences Corporation
$86
Amgen Inc.
$54
Novartis Pharmaceuticals Corporation
$50
Corcept Therapeutics
$41
Janssen Pharmaceuticals, Inc
$41
Dexcom, Inc.
$36
Phathom Pharmaceuticals, Inc.
$33
Otsuka America Pharmaceutical, Inc.
$31
SANOFI PASTEUR INC.
$29
Gilead Sciences, Inc.
$28
Abbott Laboratories
$22
AIMMUNE THERAPEUTICS, INC.
$21
Tandem Diabetes Care, Inc.
$19
SCILEX PHARMACEUTICALS INC.
$18
Kyowa Kirin, Inc.
$17
IRONWOOD PHARMACEUTICALS, INC
$15
Seqirus USA Inc
$14
Top 3 companies account for 28.7% of 2024 payments
All-time payments by company (2018-2024) ›
Novo Nordisk Inc
$1,350
GlaxoSmithKline, LLC.
$1,166
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,080
ABBVIE INC.
$975
Astellas Pharma US Inc
$952
AstraZeneca Pharmaceuticals LP
$776
Lilly USA, LLC
$653
PFIZER INC.
$645
Novartis Pharmaceuticals Corporation
$461
Bayer Healthcare Pharmaceuticals Inc.
$373
Janssen Pharmaceuticals, Inc
$339
Bayer HealthCare Pharmaceuticals Inc.
$315
AbbVie Inc.
$300
Merck Sharp & Dohme LLC
$266
Amgen Inc.
$257
ViiV Healthcare Company
$255
Abbott Laboratories
$230
Merck Sharp & Dohme Corporation
$224
Amarin Pharma Inc.
$222
Biohaven Pharmaceuticals, Inc.
$199
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$151
SANOFI-AVENTIS U.S. LLC
$148
Exact Sciences Corporation
$144
Biohaven Pharmaceutical Holding Company Ltd.
$132
ARBOR PHARMACEUTICALS, INC.
$87
Teva Pharmaceuticals USA, Inc.
$83
Otsuka America Pharmaceutical, Inc.
$79
Medtronic, Inc.
$74
E.R. Squibb & Sons, L.L.C.
$72
Neuronetics, Inc.
$71
SANOFI PASTEUR INC.
$69
Organon LLC
$65
Nestle HealthCare Nutrition Inc.
$51
Alfasigma USA, Inc.
$50
Ironwood Pharmaceuticals, Inc
$48
Esperion Therapeutics, Inc.
$45
Corcept Therapeutics
$41
Seqirus USA Inc
$40
Avanir Pharmaceuticals, Inc.
$39
Takeda Pharmaceuticals U.S.A., Inc.
$36
Dexcom, Inc.
$36
Phathom Pharmaceuticals, Inc.
$33
DEXCOM, INC.
$32
IRONWOOD PHARMACEUTICALS, INC
$32
VBI Vaccines (Delaware) Inc.
$28
Gilead Sciences, Inc.
$28
Hologic, LLC
$27
Sumitomo Pharma America, Inc.
$27
Bausch Health US, LLC
$25
AIMMUNE THERAPEUTICS, INC.
$21
Tandem Diabetes Care, Inc.
$19
SCILEX PHARMACEUTICALS INC.
$18
Edwards Lifesciences Corporation
$18
Kyowa Kirin, Inc.
$17
Genentech USA, Inc.
$17
Eisai Inc.
$16
Acerus Pharmaceuticals Corporation
$15
CooperSurgical, Inc.
$12
EISAI INC.
$12
Mylan Specialty L.P.
$11
Top 3 companies account for 27.6% of all-time payments
Associated products mentioned in payments ›
ANORO ELLIPTA · APLENZIN · APRETUDE · AREXVY · AUSTEDO · Aduhelm · Aimovig · BELSOMRA · BEXSERO · BREZTRI · CHANTIX · COMIRNATY · COSENTYX · CREON · Cologuard Collection Kit · Crysvita · DEXCOM G6 TRANSMITTER · Dayvigo · Dexcom G6 Transmitter · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · EMGALITY · ENTRESTO · EVENITY · Edarbi · FARXIGA · FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE · FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) · FLUZONE QUADRIVALENT NORTHERN HEMISPHERE · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · Fluad · Flucelvax · FreeStyle Libre 2 · GARDASIL · GARDASIL 9 · GEMTESA · Horizant · INPEN SMART INSULIN DELIVERY SYSTEM · INVOKANA · InPen · JANUVIA · JARDIANCE · Kerendia · Korlym · LEQVIO · LINZESS · Linzess · MOUNJARO · MYRBETRIQ · Myrbetriq · NEUROSTAR TMS THERAPY SYSTEM · NEXLETOL · NEXPLANON · NURTEC ODT · Natesto · Nuedexta · OFEV · Otezla · Ozempic · PAXLOVID · PNEUMOVAX 23 · PREMARIN · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · Paragard · PreHevbrio · QUADRACEL · QULIPTA · REXULTI · ROTATEQ · RYBELSUS · Rybelsus · SHINGRIX · SOLIQUA 100/33 · SPIRIVA RESPIMAT · SPRAVATO · STIOLTO RESPIMAT · SYMBICORT · SYNJARDY · SYNTHROID · THINPREP 2000 PROCESSOR · TOUJEO · TRELEGY ELLIPTA · TRINTELLIX · TRULANCE · TRULICITY · TRUMENBA · Tresiba · UBRELVY · VARIVAX · VIBERZI · VOQUEZNA · VRAYLAR · Vascepa · Veozah · Wegovy · XARELTO · XIFAXAN · Xofluza · Yupelri · ZENPEP · ZEPBOUND · ZTLido · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 2% for emergency medicine in CA.
Geographic Context
Emergency medicines within 10 mi
431
Per 100K population
104.5
County median income
$114,678
Nearest hospital
SUTTER ROSEVILLE MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kelada is a clinical cardiology specialist, with above-average Medicare volume (top 2% in CA), with low-engagement industry engagement in the top 2% of CA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kelada experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Kelada performed 674 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kelada receive payments from pharmaceutical companies?
Yes. Dr. Kelada received a total of $13,010 from 60 companies across 690 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kelada's costs compare to other emergency medicines in Roseville?
Dr. Kelada's average Medicare payment per service is $90. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kelada) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Emergency Medicines in Roseville
Browse emergency medicines in Roseville ranked by procedure volume and transparency data.
Highest volume
Top Emergency Medicines in CA
Emergency medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Emergency Medicines in CA
Which CA emergency medicines receive the most from drug and device companies.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology